title: Apalcillin treatment of complicated urinary tract infections.
abstract: In an open, prospective clinical trial, we evaluated the safety and efficacy of apalcillin in the treatment of complicated urinary tract infection. 21 hospitalized adult patients received apalcillin 2 g IV Q8-12 h for 5-17 days. There were 8 upper tract and 13 lower tract infections. Of 25 functional or anatomic abnormalities of the GU tract among these patients, 9 (36%) were corrected during the study period. Effectiveness of apalcillin was determined by clinical and bacteriologic response. 16 (76.2%) patients had clinical cures, 4 (19.8%) had clinical improvement, and 1 (4.8%) had clinical failure. Based on 26 pretreatment isolates, there were 16 (61.5%) bacteriologic cures and 10 (38.5%) failures. Failures were due to 6 (23.1%) relapses, 2 (7.7%) superinfections, and 2 (7.7%) relapses with superinfection. Adverse reactions were mild, transient, and did not require discontinuation of treatment. Apalcillin appears to be a safe, although marginally effective single agent antibiotic for the treatment of complicated urinary tract infections.
authors.forename: R
authors.initials: R
authors.lastname: Sharifi
authors.forename: L
authors.initials: L
authors.lastname: Ojeda
authors.forename: M
authors.initials: M
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009287:Naphthyridines; D011446:Prospective Studies; D011512:Proteus Infections / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000188:drug therapy; D012008:Recurrence; D014552:Urinary Tract Infections / Q000188:drug therapy*
chemical_list: D009287:Naphthyridines; C012122:apalcillin; D000667:Ampicillin